Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EXEL 
Exelixis Inc (EXEL)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EXEL (5-star) is a STRONG-BUY. BUY since 12 days. Profits (5.51%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
20 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $44.47
Year Target Price $44.47
| 7 | Strong Buy |
| 4 | Buy |
| 9 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 65.89% | Avg. Invested days 47 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.02B USD | Price to earnings Ratio 20.13 | 1Y Target Price 44.47 |
Price to earnings Ratio 20.13 | 1Y Target Price 44.47 | ||
Volume (30-day avg) 20 | Beta 0.28 | 52 Weeks Range 21.82 - 49.62 | Updated Date 06/30/2025 |
52 Weeks Range 21.82 - 49.62 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.99% | Operating Margin (TTM) 33.64% |
Management Effectiveness
Return on Assets (TTM) 18.05% | Return on Equity (TTM) 30.22% |
Valuation
Trailing PE 20.13 | Forward PE 21.83 | Enterprise Value 11064979587 | Price to Sales(TTM) 5.23 |
Enterprise Value 11064979587 | Price to Sales(TTM) 5.23 | ||
Enterprise Value to Revenue 4.81 | Enterprise Value to EBITDA 13.11 | Shares Outstanding 272708000 | Shares Floating 232276550 |
Shares Outstanding 272708000 | Shares Floating 232276550 | ||
Percent Insiders 2.2 | Percent Institutions 94.07 |
Analyst Ratings
Rating 5 | Target Price 44.47 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold 9 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Exelixis Inc
Company Overview
History and Background
Exelixis, Inc. was founded in 1994. It is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to treat cancer.
Core Business Areas
- Oncology: Exelixis is dedicated to the discovery, development, and commercialization of oncology drugs.
- Research and Development: Focuses on creating a pipeline of novel therapies.
- Commercialization: Commercializing and marketing its own drugs, primarily in the United States.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry, with a board of directors providing strategic oversight. The organizational structure is based on functional departments, including R&D, commercial operations, and corporate support.
Top Products and Market Share
Key Offerings
- CABOMETYX (cabozantinib): CABOMETYX is a tyrosine kinase inhibitor (TKI) approved for advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). Competitors include therapies from Pfizer (Sutent), Bristol Myers Squibb (Opdivo), and Merck (Keytruda). Exelixis reported $1.46 billion in CABOMETYX revenue in 2023. CABOMETYX holds a significant market share in the RCC market.
- COMETRIQ (cabozantinib): COMETRIQ is also a formulation of cabozantinib, indicated for progressive, metastatic medullary thyroid cancer (MTC). Market share is smaller than CABOMETYX due to the rarity of MTC. Competitors are similar, but this market is niche. COMETRIQ revenue is substantially smaller than Cabometyx
Market Dynamics
Industry Overview
The oncology drug market is large and growing, driven by an aging population and advances in cancer treatment. It is highly competitive and innovative.
Positioning
Exelixis is a mid-sized player focused on kinase inhibitors. Its competitive advantage lies in the proven efficacy of cabozantinib and its focus on specific cancers.
Total Addressable Market (TAM)
The global oncology market is expected to reach several hundred billion USD. Exelixis is positioned within specific segments like RCC, HCC, and thyroid cancer, with potential for expansion into other indications.
Upturn SWOT Analysis
Strengths
- Successful commercialization of CABOMETYX
- Strong intellectual property position
- Experienced management team
- Established research and development capabilities
- Diverse pipeline of potential therapies
Weaknesses
- Reliance on a limited number of products
- Exposure to generic competition upon patent expiry
- Dependence on partnerships for certain drug development programs
- High research and development expenses
Opportunities
- Expansion into new indications for CABOMETYX
- Development of novel therapies in oncology
- Strategic acquisitions or partnerships
- Geographic expansion into new markets
- Advancements in diagnostics to improve patient selection
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
- Pricing pressures and reimbursement challenges
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- PFE
- BMY
- MRK
- AZN
Competitive Landscape
Exelixis competes with larger pharmaceutical companies in the oncology space. It differentiates itself through its focus on specific kinase inhibitors and its development of targeted therapies. Its smaller size allows it to be more nimble, but it lacks the resources of larger competitors.
Major Acquisitions
Kinnate Biopharma
- Year: 2024
- Acquisition Price (USD millions): 108
- Strategic Rationale: Expanded pipeline of next-generation RAF inhibitors to address unmet needs in the treatment of cancer. Increases Exelixis' footprint in the RAF inhibitor market.
Growth Trajectory and Initiatives
Historical Growth: Exelixis has experienced substantial revenue growth in recent years, driven by the successful launch and expansion of CABOMETYX.
Future Projections: Analyst estimates project continued revenue growth, albeit at a slower pace. Future growth will depend on new product launches, label expansions, and market penetration.
Recent Initiatives: Recent initiatives include ongoing clinical trials to evaluate CABOMETYX in new indications, partnerships to expand the pipeline, and efforts to optimize manufacturing and distribution.
Summary
Exelixis has a strong position in the oncology market with its drug CABOMETYX, contributing to its revenue and growth. The company needs to successfully expand its product line and be wary of larger competitors and patent expirations. Strategic initiatives, such as acquisitions can further diversify their market reach. The financial health of the company allows it to pursue future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Exelixis Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- Yahoo Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1147 | Website https://www.exelixis.com |
Full time employees 1147 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.